Vontobel Holding Ltd. Sells 22,676 Shares of Becton, Dickinson and Company (NYSE:BDX)

Vontobel Holding Ltd. trimmed its stake in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 26.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,106 shares of the medical instruments supplier’s stock after selling 22,676 shares during the period. Vontobel Holding Ltd.’s holdings in Becton, Dickinson and were worth $14,043,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in BDX. Fairfield Bush & CO. bought a new position in shares of Becton, Dickinson and in the 1st quarter worth $114,000. Sequoia Financial Advisors LLC increased its position in Becton, Dickinson and by 11.3% during the 1st quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier’s stock valued at $778,000 after buying an additional 297 shares in the last quarter. Brighton Jones LLC increased its position in Becton, Dickinson and by 8.8% during the 1st quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $368,000 after buying an additional 112 shares in the last quarter. Zions Bancorporation N.A. increased its position in Becton, Dickinson and by 13.0% during the 1st quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier’s stock valued at $134,000 after buying an additional 58 shares in the last quarter. Finally, Mather Group LLC. increased its position in Becton, Dickinson and by 26.0% during the 1st quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier’s stock valued at $358,000 after buying an additional 278 shares in the last quarter. 87.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on BDX shares. StockNews.com lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Cowen reduced their target price on Becton, Dickinson and to $255.00 in a research report on Wednesday, November 16th. The Goldman Sachs Group reduced their target price on Becton, Dickinson and from $319.00 to $272.00 and set a “buy” rating on the stock in a research report on Wednesday, November 23rd. Citigroup raised Becton, Dickinson and from a “sell” rating to a “neutral” rating and increased their price objective for the company from $221.00 to $250.00 in a report on Monday, December 12th. Finally, Bank of America raised Becton, Dickinson and from a “neutral” rating to a “buy” rating and increased their price objective for the company from $250.00 to $290.00 in a report on Tuesday, January 3rd. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $273.82.

Becton, Dickinson and Stock Down 1.5 %

Shares of BDX opened at $245.75 on Wednesday. Becton, Dickinson and Company has a 52 week low of $215.90 and a 52 week high of $280.62. The company has a quick ratio of 0.63, a current ratio of 1.04 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $69.86 billion, a price-to-earnings ratio of 41.79, a PEG ratio of 2.19 and a beta of 0.58. The stock’s 50-day moving average price is $248.71 and its 200-day moving average price is $243.88.

Becton, Dickinson and (NYSE:BDXGet Rating) last issued its earnings results on Thursday, November 10th. The medical instruments supplier reported $2.75 EPS for the quarter, topping analysts’ consensus estimates of $2.73 by $0.02. Becton, Dickinson and had a return on equity of 14.47% and a net margin of 9.16%. The firm had revenue of $4.76 billion for the quarter, compared to the consensus estimate of $4.72 billion. During the same quarter in the prior year, the business earned $2.15 earnings per share. The company’s revenue was down 6.6% compared to the same quarter last year. On average, sell-side analysts predict that Becton, Dickinson and Company will post 11.93 EPS for the current year.

Becton, Dickinson and Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 31st. Stockholders of record on Friday, March 10th will be paid a $0.91 dividend. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s payout ratio is 61.90%.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.